

THIS ANNOUNCEMENT (INCLUDING THE APPENDICES) AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR PUBLICATION, RELEASE OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES OF AMERICA, ITS STATES, TERRITORIES AND POSSESSIONS (UNITED STATES), AUSTRALIA, CANADA, JAPAN, SINGAPORE, THE REPUBLIC OF SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH SUCH PUBLICATION, RELEASE OF DISTRIBUTION WOULD BE PROHIBITED BY ANY APPLICABLE LAW.

THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER TO SELL OR ISSUE OR THE SOLICITATION TO BUY, SUBSCRIBE FOR OR OTHERWISE ACQUIRE ANY SECURITIES.

**THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATION (EU) 596/2014 AS IT FORMS PART OF UK DOMESTIC LAW BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018 ("MAR"), AND IS DISCLOSED IN ACCORDANCE WITH THE COMPANY'S OBLIGATIONS UNDER ARTICLE 17 OF MAR.**

**Sareum Holdings PLC**

("Sareum" or the "Company")

**Institutional Equity Fundraise**

**Cambridge, UK, 13<sup>th</sup> March 2025** - Sareum Holdings plc (AIM: SAR), a clinical-stage biotechnology company developing next-generation kinase inhibitors for autoimmune disease and cancer, announces that it has conditionally raised gross proceeds of £1.07 million by means of a subscription (the "**Subscription**") for 8,560,000 new ordinary shares of 1.25 pence each in the capital of the Company ("**Ordinary Shares**") with an institution (the "**Subscription Shares**") at a price of 12.5 pence per new Ordinary Share (the "**Subscription Price**"). The net proceeds from the Subscription will be used to support the development of the expanded portfolio and for general working capital purposes.

The Subscription Price represents a discount of approximately 24% to the closing mid- market price for Sareum shares on 12<sup>th</sup> March 2025.

**Admission and Total Voting Rights**

The Company has applied for 8,560,000 Subscription Shares to be admitted to trading on AIM ("**Admission**") by 8.00 a.m. on or around 18<sup>th</sup> March 2025.

The Subscription Shares will, when issued, be credited as fully paid and will rank *pari passu* in all respects with the existing Ordinary Shares of the Company including the right to receive all dividends or other distributions made, paid or declared in respect of such shares after Admission. Admission is conditional on all funds having been received from subscribers pursuant to the Subscription.

Following Admission, the total number of Ordinary Shares in issue will be 133,487,651 and the total number of voting rights will thereafter be 133,487,651 and this figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.

**Dr Stephen Parker, Executive Chairman of Sareum, commented:** "We are delighted by the continued support and look forward to developing the portfolio, now including SRA737, as we look to build value for our shareholders."

- Ends -

**For further information, please contact:**

**Sareum Holdings plc**  
stephen Parker, Executive Chairman

01223 497700  
ir@sareum.co.uk

**Strand Hanson Limited (Nominated Adviser)**  
James Dance / James Bellman

020 7409 3494

**Oberon Capital (Joint Broker)**  
Mike Seabrook / Nick Lovering

0203 179 5300

**Hybridan LLP (Joint Broker)**  
Claire Noyce

020 3764 2341

**ICR Healthcare (Financial PR)**  
Jessica Hodgson / Davide Salvi

0203 709 5700

#### **About Sareum**

Sareum (AIM: SAR) is a biotechnology company developing next generation kinase inhibitors for autoimmune disease and cancer.

The Company is focused on developing next generation small molecules which modify the activity of the JAK kinase family and have best-in-class potential. Its lead candidate, SDC-1801, simultaneously inhibits TYK2 and JAK1. SDC-1801 is a potential treatment for a range of autoimmune diseases, including psoriasis, and has completed Phase 1 clinical development.

Sareum is also developing SDC-1802, a TYK2/JAK1 inhibitor with a potential application for cancer immunotherapy.

Sareum Holdings plc is based in Cambridge, UK, and is quoted on the AIM market of the London Stock Exchange, trading under the ticker SAR. For further information, please visit the Company's website at [www.sareum.com](http://www.sareum.com).

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [ms@seg.com](mailto:ms@seg.com) or visit [www.ms.com](http://www.ms.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

IOEEAXDDFFDSEEA